|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®) Head and Neck Cancers. (Version 1.2016).
http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdfAugust
5–2016
|
|
4
|
Zhong LP and Zhang ZY: Reply to K.
Devisetty et al. J Clin Oncol. 31:2972–2973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhong LP, Zhang CP, Ren GX, Guo W, William
WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai YL, et al: Randomized phase
III trial of induction chemotherapy with docetaxel, cisplatin, and
fluorouracil followed by surgery versus up-front surgery in locally
advanced resectable oral squamous cell carcinoma. J Clin Oncol.
31:744–751. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhong LP, Zhang CP, Ren GX, Guo W, William
WN Jr, Hong CS, Sun J, Zhu HG, Tu WY, Li J, et al: Long-term
results of a randomized phase III trial of TPF induction
chemotherapy followed by surgery and radiotherapy in locally
advanced oral squamous cell carcinoma. Oncotarget. 6:18707–18714.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Breit SN, Johnen H, Cook AD, Tsai VW,
Mohammad MG, Kuffner T, Zhang HP, Marquis CP, Jiang L, Lockwood G,
et al: The TGF-β superfamily cytokine, MIC-1/GDF15: A pleotrophic
cytokine with roles in inflammation, cancer and metabolism. Growth
Factors. 29:187–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corre J, Hebraud B and Bourin P: Concise
review: Growth differentiation factor 15 in pathology: A clinical
role? Stem Cells Transl Med. 2:946–952. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khaled YS, Elkord E and Ammori BJ:
Macrophage inhibitory cytokine-1: A review of its pleiotropic
actions in cancer. Cancer Biomark. 11:183–190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brown DA, Lindmark F, Stattin P, Bälter K,
Adami HO, Zheng SL, Xu J, Isaacs WB, Grönberg H, Breit SN and
Wiklund FE: Macrophage inhibitory cytokine 1: A new prognostic
marker in prostate cancer. Clin Cancer Res. 15:6658–6664. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wallin U, Glimelius B, Jirstrom K,
Darmanis S, Nong RY, Pontén F, Johansson C, Påhlman L and Birgisson
H: Growth differentiation factor 15: A prognostic marker for
recurrence in colorectal cancer. Br J Cancer. 104:1619–1627. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang L, Yang X, Pan HY, Zhou XJ, Li J,
Chen WT, Zhong LP and Zhang ZY: Expression of growth
differentiation factor 15 is positively correlated with
histopathological malignant grade and in vitro cell proliferation
in oral squamous cell carcinoma. Oral Oncol. 45:627–632. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brown DA, Stephan C, Ward RL, Law M,
Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM, et
al: Measurement of serum levels of macrophage inhibitory cytokine 1
combined with prostate-specific antigen improves prostate cancer
diagnosis. Clin Cancer Res. 12:89–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Selander KS, Brown DA, Sequeiros GB,
Hunter M, Desmond R, Parpala T, Risteli J, Breit SN and
Jukkola-Vuorinen A: Serum macrophage inhibitory cytokine-1
concentrations correlate with the presence of prostate cancer bone
metastases. Cancer Epidemiol Biomarkers Prev. 16:532–537. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brown DA, Ward RL, Buckhaults P, Liu T,
Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B and
Breit SN: MIC-1 serum level and genotype: Associations with
progress and prognosis of colorectal carcinoma. Clin Cancer Res.
9:2642–2650. 2003.PubMed/NCBI
|
|
16
|
Schiegnitz E, Kämmerer PW, Koch FP, Kruger
M, Berres M and Al-Nawas B: GDF 15 as an anti-apoptotic, diagnostic
and prognostic marker in oral squamous cell carcinoma. Oral Oncol.
48:608–614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schiegnitz E, Kämmerer PW, Rode K, Schorn
T, Brieger J and Al-Nawas B: Growth differentiation factor 15 as a
radiation-induced marker in oral carcinoma increasing radiation
resistance. J Oral Pathol Med. 45:63–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shnaper S, Desbaillets I, Brown DA, Murat
A, Migliavacca E, Schluep M, Ostermann S, Hamou MF, Stupp R, Breit
SN, et al: Elevated levels of MIC-1/GDF15 in the cerebrospinal
fluid of patients are associated with glioblastoma and worse
outcome. Int J Cancer. 125:2624–2630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang CZ, Ma J, Zhu DW, Montgomery B, Wang
LZ, Li J, Zhang ZY, Zhang CP and Zhong LP: GDF15 is a potential
predictive biomarker for TPF induction chemotherapy and promotes
tumorigenesis and progression in oral squamous cell carcinoma. Ann
Oncol. 25:1215–1222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sobin LH and Wittekind CH: International
Union Against Cancer (UICC): TNM classification of malignant
tumours. 6th edition. Wiley; New York, NY: 2002
|
|
21
|
Kaemmerer D, Peter L, Lupp A, Schulz S,
Sänger J, Baum RP, Prasad V and Hommann M: Comparing of IRS and
Her2 as immunohistochemical scoring schemes in
gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp
Pathol. 5:187–194. 2012.PubMed/NCBI
|
|
22
|
Arduino PG, Carrozzo M, Chiecchio A,
Broccoletti R, Tirone F, Borra E, Bertolusso G and Gandolfo S:
Clinical and histopathologic independent prognostic factors in oral
squamous cell carcinoma: A retrospective study of 334 cases. J Oral
Maxillofac Surg. 66:1570–1579. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhong LP, Zhu DW, William WN Jr, Liu Y, Ma
J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, et al: Elevated cyclin
D1 expression is predictive for a benefit from TPF induction
chemotherapy in oral squamous cell carcinoma patients with advanced
nodal disease. Mol Cancer Ther. 12:1112–1121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Staff AC, Bock AJ, Becker C, Kempf T,
Wollert KC and Davidson B: Growth differentiation factor-15 as a
prognostic biomarker in ovarian cancer. Gynecol Oncol. 118:237–243.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao L, Lee BY, Brown DA, Molloy MP, Marx
GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, et al:
Identification of candidate biomarkers of therapeutic response to
docetaxel by proteomic profiling. Cancer Res. 69:7696–7703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim IY, Park SY, Kang Y, Thapa D, Choi HG
and Kim JA: Role of nonsteroidal anti-inflammatory drug-activated
gene-1 in docetaxel-induced cell death of human colorectal cancer
cells with different p53 status. Arch Pharm Res. 34:323–330. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Proutski I, Stevenson L, Allen WL, McCulla
A, Boyer J, McLean EG, Longley DB and Johnston PG: Prostate-derived
factor-a novel inhibitor of drug-induced cell death in colon cancer
cells. Mol Cancer Ther. 8:2566–2574. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Magadoux L, Isambert N, Plenchette S,
Jeannin JF and Laurens V: Emerging targets to monitor and overcome
docetaxel resistance in castration resistant prostate cancer
(review). Int J Oncol. 45:919–928. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mahon KL, Lin HM, Castillo L, Lee BY,
Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, et
al: Cytokine profiling of docetaxel-resistant castration-resistant
prostate cancer. Br J Cancer. 112:1340–1348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hitt R, Grau JJ, López-Pousa A, Berrocal
A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J,
Castelo Brandariz JA, Verger E, et al: A randomized phase III trial
comparing induction chemotherapy followed by chemoradiotherapy
versus chemoradiotherapy alone as treatment of unresectable head
and neck cancer. Ann Oncol. 25:216–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haddad R, O'Neill A, Rabinowits G, Tishler
R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, et
al: Induction chemotherapy followed by concurrent chemoradiotherapy
(sequential chemoradiotherapy) versus concurrent chemoradiotherapy
alone in locally advanced head and neck cancer (PARADIGM): A
randomised phase 3 trial. Lancet Oncol. 14:257–264. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cohen EE, Karrison TG, Kocherginsky M,
Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB,
Yunus F, et al: Phase III randomized trial of induction
chemotherapy in patients with N2 or N3 locally advanced head and
neck cancer. J Clin Oncol. 32:2735–2743. 2014. View Article : Google Scholar : PubMed/NCBI
|
